Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral Therapy To Take Share In Second-line Hormone-refractory Prostate Cancer Market

Published by: Datamonitor

Published: May. 31, 2006 - 12 Pages


Table of Contents


SUMMARY
SPPI's Oral Satraplatin aims to take share in underserved second-line HRPC market


COMPANY BACKGROUND
Spectrum Pharmaceuticals
Satraplatin


HORMONE REFRACTORY PROSTATE CANCER
Overview
Taxotere: Standard of care for hormone refractory prostate cancer patients
Satraplatin shows potential in HRPC
Phase III trial designed to support eventual FDA approval


FACTORS AFFECTING THE POTENTIAL FOR SATRAPLATIN
Lack of approved second-line HRPC agents should help near-term potential
Can activity in Phase II be replicated in Phase III trial?
Oral formulation could actually hinder uptake in HRPC


DATAMONITOR SATRAPLATIN FORECAST
Given known activity and unmet need, approval seems likely
First approved second-line HRPC agent could have great potential
Future front-line and combination use could represent further upside


APPENDIX
Supplementary data
Datamonitor Healthcare
Disclosure information
Ask the analyst


List of Tables
Table 1: Forecast US Satraplatin revenues 2007-2011
Table 2: US Hormone Refractory Prostate Cancer Model

Abstract

Introduction

There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.

Scope
  • Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
  • Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option
Highlights

Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.

Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.

Reasons to Purchase
  • Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008